KMT2A and leukemia: Selected inhibitors were found to suppress expression of MLL target genes HoxA9, Meis1 and Myc and inhibit proliferation of MLL-r leukemia and other AML cells with EC50s as low as 4.7 μM, while they were inactive against solid tumor Hela cells.